Is SYRE or CMPS more profitable?

Compass Pathways' return on equity of -31.07% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Compass Pathways N/A -31.07% -11.40%

Does the media refer more to SYRE or CMPS?

In the previous week, Spyre Therapeutics had 7 more articles in the media than Compass Pathways. MarketBeat recorded 11 mentions for Spyre Therapeutics and 4 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.72 beat Spyre Therapeutics' score of 0.26 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, CMPS or IMVT?

Immunovant is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compass Pathways N/A N/A -$287.86M -$3.15 N/A Immunovant N/A N/A -$505.61M -$2.78 N/A

Is CMPS or IMVT more profitable?

Compass Pathways' return on equity of -31.07% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Compass Pathways N/A -31.07% -11.40% Immunovant N/A -65.66% -59.88%

Does the media favor CMPS or IMVT?

In the previous week, Immunovant had 1 more articles in the media than Compass Pathways. MarketBeat recorded 5 mentions for Immunovant and 4 mentions for Compass Pathways. Immunovant's average media sentiment score of 1.64 beat Compass Pathways' score of 0.72 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor CMPS or PTGX?

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Compass Pathways. MarketBeat recorded 5 mentions for Protagonist Therapeutics and 4 mentions for Compass Pathways. Protagonist Therapeutics' average media sentiment score of 1.23 beat Compass Pathways' score of 0.72 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CMPS or TGTX?

In the previous week, TG Therapeutics had 9 more articles in the media than Compass Pathways. MarketBeat recorded 13 mentions for TG Therapeutics and 4 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.72 beat TG Therapeutics' score of 0.69 indicating that Compass Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KYMR or CMPS?

In the previous week, Kymera Therapeutics had 5 more articles in the media than Compass Pathways. MarketBeat recorded 9 mentions for Kymera Therapeutics and 4 mentions for Compass Pathways. Kymera Therapeutics' average media sentiment score of 0.75 beat Compass Pathways' score of 0.72 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Compass Pathways (CMPS) Competitors

$11.03 -0.23 (-2.04%)

Closing price 04:00 PM Eastern

Extended Trading

$11.08 +0.05 (+0.45%)

As of 07:40 PM Eastern

Compare

CMPS vs. SYRE, IMVT, PTGX, TGTX, and KYMR

Should you buy Compass Pathways stock or one of its competitors? MarketBeat compares Compass Pathways with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Compass Pathways include Spyre Therapeutics (SYRE), Immunovant (IMVT), Protagonist Therapeutics (PTGX), TG Therapeutics (TGTX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

How does Compass Pathways compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Compass Pathways (NASDAQ:CMPS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 2.8% of Compass Pathways shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Compass Pathways' return on equity of -31.07% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Compass Pathways	N/A	-31.07%	-11.40%

Spyre Therapeutics currently has a consensus price target of $91.33, suggesting a potential upside of 21.65%. Compass Pathways has a consensus price target of $21.36, suggesting a potential upside of 93.69%. Given Compass Pathways' higher probable upside, analysts clearly believe Compass Pathways is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Spyre Therapeutics has higher revenue and earnings than Compass Pathways. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	7,325.78	-$155.20M	-$2.08	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

In the previous week, Spyre Therapeutics had 7 more articles in the media than Compass Pathways. MarketBeat recorded 11 mentions for Spyre Therapeutics and 4 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.72 beat Spyre Therapeutics' score of 0.26 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has a beta of 3.05, meaning that its stock price is 205% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market.

Summary

Spyre Therapeutics beats Compass Pathways on 8 of the 13 factors compared between the two stocks.

How does Compass Pathways compare to Immunovant?

Compass Pathways (NASDAQ:CMPS) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Compass Pathways has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Immunovant is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Compass Pathways' return on equity of -31.07% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Immunovant	N/A	-65.66%	-59.88%

Compass Pathways currently has a consensus price target of $21.36, suggesting a potential upside of 93.69%. Immunovant has a consensus price target of $37.33, suggesting a potential upside of 19.73%. Given Compass Pathways' stronger consensus rating and higher possible upside, research analysts clearly believe Compass Pathways is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, Immunovant had 1 more articles in the media than Compass Pathways. MarketBeat recorded 5 mentions for Immunovant and 4 mentions for Compass Pathways. Immunovant's average media sentiment score of 1.64 beat Compass Pathways' score of 0.72 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

46.2% of Compass Pathways shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by company insiders. Comparatively, 1.8% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Compass Pathways beats Immunovant on 10 of the 14 factors compared between the two stocks.

How does Compass Pathways compare to Protagonist Therapeutics?

Compass Pathways (NASDAQ:CMPS) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Compass Pathways. MarketBeat recorded 5 mentions for Protagonist Therapeutics and 4 mentions for Compass Pathways. Protagonist Therapeutics' average media sentiment score of 1.23 beat Compass Pathways' score of 0.72 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compass Pathways has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

46.2% of Compass Pathways shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 2.8% of Compass Pathways shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Compass Pathways has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market.

Compass Pathways presently has a consensus target price of $21.36, suggesting a potential upside of 93.69%. Protagonist Therapeutics has a consensus target price of $115.21, suggesting a potential upside of 8.93%. Given Compass Pathways' stronger consensus rating and higher possible upside, equities research analysts clearly believe Compass Pathways is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Protagonist Therapeutics has higher revenue and earnings than Compass Pathways. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Protagonist Therapeutics	$46.02M	147.81	-$130.15M	-$1.81	N/A

Summary

Protagonist Therapeutics beats Compass Pathways on 9 of the 16 factors compared between the two stocks.

How does Compass Pathways compare to TG Therapeutics?

Compass Pathways (NASDAQ:CMPS) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Compass Pathways currently has a consensus price target of $21.36, suggesting a potential upside of 93.69%. TG Therapeutics has a consensus price target of $52.50, suggesting a potential upside of 12.61%. Given Compass Pathways' stronger consensus rating and higher possible upside, research analysts clearly believe Compass Pathways is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, TG Therapeutics had 9 more articles in the media than Compass Pathways. MarketBeat recorded 13 mentions for TG Therapeutics and 4 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.72 beat TG Therapeutics' score of 0.69 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

46.2% of Compass Pathways shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

TG Therapeutics has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
TG Therapeutics	$616.29M	11.58	$447.18M	$2.86	16.30

Compass Pathways has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

TG Therapeutics has a net margin of 65.95% compared to Compass Pathways' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
TG Therapeutics	65.95%	88.73%	43.44%

Summary

TG Therapeutics beats Compass Pathways on 10 of the 16 factors compared between the two stocks.

How does Compass Pathways compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Compass Pathways (NASDAQ:CMPS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Kymera Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, indicating that its stock price is 150% more volatile than the broader market.

46.2% of Compass Pathways shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 2.8% of Compass Pathways shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Compass Pathways has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Compass Pathways	N/A	-31.07%	-11.40%

Kymera Therapeutics presently has a consensus target price of $117.14, suggesting a potential upside of 49.73%. Compass Pathways has a consensus target price of $21.36, suggesting a potential upside of 93.69%. Given Compass Pathways' higher possible upside, analysts clearly believe Compass Pathways is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

In the previous week, Kymera Therapeutics had 5 more articles in the media than Compass Pathways. MarketBeat recorded 9 mentions for Kymera Therapeutics and 4 mentions for Compass Pathways. Kymera Therapeutics' average media sentiment score of 0.75 beat Compass Pathways' score of 0.72 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compass Pathways has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	164.12	-$311.35M	-$3.57	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

Summary

Compass Pathways beats Kymera Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Compass Pathways News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPS vs. The Competition

Export

Metric	Compass Pathways	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.52B	$8.99B	$6.50B	$11.95B
Dividend Yield	N/A	1.73%	2.67%	5.61%
P/E Ratio	-3.50	24.39	24.65	23.63
Price / Sales	N/A	18.41	500.87	105.21
Price / Cash	N/A	90.88	43.05	54.72
Price / Book	-20.05	5.45	10.43	6.70
Net Income	-$287.86M	$179.69M	$3.56B	$337.26M
7 Day Performance	-13.08%	0.42%	-1.39%	-1.41%
1 Month Performance	11.30%	5.97%	0.86%	1.15%
1 Year Performance	131.72%	0.72%	19.42%	22.61%

Compass Pathways Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMPS Compass Pathways	3.0595 of 5 stars	$11.03 -2.0%	$21.36 +93.7%	+141.1%	$1.52B	N/A	N/A	120
SYRE Spyre Therapeutics	2.2384 of 5 stars	$72.00 -2.2%	$91.33 +26.9%	+345.5%	$6.40B	$890K	N/A	73
IMVT Immunovant	3.753 of 5 stars	$30.80 -1.0%	$37.33 +21.2%	+94.0%	$6.39B	N/A	N/A	120	Positive News
PTGX Protagonist Therapeutics	1.8086 of 5 stars	$98.03 +0.7%	$115.21 +17.5%	+90.1%	$6.26B	$46.02M	N/A	120	Positive News
TGTX TG Therapeutics	2.7802 of 5 stars	$40.95 +2.0%	$52.50 +28.2%	+8.9%	$6.15B	$616.29M	14.32	290	Trending News Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMPS) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compass Pathways (CMPS) Competitors

CMPS vs. SYRE, IMVT, PTGX, TGTX, and KYMR

How does Compass Pathways compare to Spyre Therapeutics?

Summary

How does Compass Pathways compare to Immunovant?

Summary

How does Compass Pathways compare to Protagonist Therapeutics?

Summary

How does Compass Pathways compare to TG Therapeutics?

Summary

How does Compass Pathways compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compass Pathways (CMPS) Competitors

CMPS vs. SYRE, IMVT, PTGX, TGTX, and KYMR

How does Compass Pathways compare to Spyre Therapeutics?

Do insiders & institutionals hold more shares of SYRE or CMPS?

Is SYRE or CMPS more profitable?

Do analysts rate SYRE or CMPS?

Which has higher earnings & valuation, SYRE or CMPS?

Does the media refer more to SYRE or CMPS?

Which has more risk & volatility, SYRE or CMPS?

Summary

How does Compass Pathways compare to Immunovant?

Which has more risk and volatility, CMPS or IMVT?

Which has higher earnings and valuation, CMPS or IMVT?

Is CMPS or IMVT more profitable?

Do analysts rate CMPS or IMVT?

Does the media favor CMPS or IMVT?

Do institutionals and insiders hold more shares of CMPS or IMVT?

Summary

How does Compass Pathways compare to Protagonist Therapeutics?

Does the media favor CMPS or PTGX?

Is CMPS or PTGX more profitable?

Do insiders and institutionals have more ownership in CMPS or PTGX?

Which has more volatility and risk, CMPS or PTGX?

Do analysts rate CMPS or PTGX?

Which has stronger earnings & valuation, CMPS or PTGX?

Summary

How does Compass Pathways compare to TG Therapeutics?

Do analysts prefer CMPS or TGTX?

Does the media prefer CMPS or TGTX?

Do institutionals and insiders hold more shares of CMPS or TGTX?

Which has better earnings and valuation, CMPS or TGTX?

Which has more volatility and risk, CMPS or TGTX?

Is CMPS or TGTX more profitable?

Summary

How does Compass Pathways compare to Kymera Therapeutics?

Which has more risk and volatility, KYMR or CMPS?

Do institutionals & insiders have more ownership in KYMR or CMPS?

Is KYMR or CMPS more profitable?

Do analysts recommend KYMR or CMPS?

Does the media favor KYMR or CMPS?

Which has stronger valuation and earnings, KYMR or CMPS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools